APA (7th ed.) Citation

Dobson, L. J., Hock, B. D., Drabble, A. H., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15(5), 1. https://doi.org/10.1002/cti2.70098

Chicago Style (17th ed.) Citation

Dobson, Lachlan J., Barry D. Hock, Ariana HT Drabble, Liping Goddard, Judith L. McKenzie, Sean A. MacPherson, and Alexander D. McLellan. "Enhanced Fc and Complement Activity of Fc‐modified Avelumab Boosts Anti‐tumor Activity but Promotes NK Cell Fratricide." Clinical & Translational Immunology 15, no. 5 (2026): 1. https://doi.org/10.1002/cti2.70098.

MLA (9th ed.) Citation

Dobson, Lachlan J., et al. "Enhanced Fc and Complement Activity of Fc‐modified Avelumab Boosts Anti‐tumor Activity but Promotes NK Cell Fratricide." Clinical & Translational Immunology, vol. 15, no. 5, 2026, p. 1, https://doi.org/10.1002/cti2.70098.